Express Mail EF203336755US Serial No.: 09/775,743

Ord.

 Y_5 is aromatic amino acid comprising of Trp, Phe, Tyr or His Y_6 is aromatic amino acid comprising of Tyr Trp, Phe or His X is any amino acid,

said compound being capable of specific binding with the high affinity VEGF receptor.

- 26. (new) The pharmaceutical compound of claim 25, wherein the amino acid sequence has the formula of SEQ. ID. NO.:1.
- 27. (new) The pharmaceutical compound of claim 25, wherein the amino acid sequence has the formula of SEQ. ID. NO.:2.
- 28. (new) The pharmaceutical compound of claim 25, wherein the amino acid sequence has the formula of SEQ. ID. NO.
- 29. (new) The pharmaceutical compound of claim 25, wherein the amino acid sequence has the formula of SEQ. ID. MO.:4.
- 30. (new) The pharmaceutical compound of claim 25, wherein the amino acid sequence has the formula of SEQ. ID. NO.:5.
- 31. (new) The pharmaceutical compound of claim 25, wherein the amino acid sequence has the formula of SEQ. ID. NO.:7.
- 32. (new) A pharmaceutical composition comprising the compound of claim 25 and a biological agent.
- 33. (new) A pharmaceutical composition comprising the compound of claim 25 and a carrier.
- 34. (new)/The pharmaceutical compound of claim 25, wherein a biological agent conjugated to said sequence ID. NO.:8.

Express Mail EF203336755US Serial No.: 09/775,743



- 35. (new) The pharmaceutical compound of claim 25, wherein the compound further comprises a modified biological agent conjugated to said sequence ID. NO.:8.
- 36. (new) The pharmaceutical compound of claim 25, wherein a therapeutic agent is conjugated to said sequence ID. NO.:8.
- 37. (new) A method of treating a disease associated with angiogenesis in a patient in need of such therapy comprising administering to said patient an effective amount of said pharmaceutical compound of claim 25 and a pharmaceutical acceptable carrier.
- 38. (new) An isolated nucleic acid encoding the polypeptide or derivative thereof comprising amino acid sequences of SEQ. ID. NOs.: 1, 2, 3, 4, 5, 7 or 8.
- 39. (new) An expression vector comprising the nucleic acid sequences of claim 38.
- 40. (new) A host cell transfected with the expression vector of claim 38.
- 41. (new) A composition comprising a nucleic acid molecule and carrier, wherein the nucleic acid molecule encodes a polypeptide encoding the amino acid sequence of SEQ. ID. Nos.: 1, 2, 3, 4, 5, 7 or 8.

REMARKS

Cfaims 1-24 have been canceled and new claims 26-41 have been added. These claims substantially correspond to the claims 1-24 already present in the case except that they present the claimed subject matter in better form for U.S. prosecution claim 1 which uses functional language and terms and which uses such derivatives has been canceled. It is believed that these claims present the invention in better form for U.S. examination.